Small molecule · developed by Tonix Pharmaceuticals
TNX-102-A is a sublingual tablet formulation given at 2.4 mg, held under the tongue until it dissolves.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01689259 | Phase 1 | Healthy Adults | Completed | TNXP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Adults
Updated Nov 1, 2026. Something wrong or missing? Report it on the TNXP page.
See TNXP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TNXP catalysts and pipeline →